Biology subjects

Taha, M.

Publications and source records attributed to Taha, M..

5 recordsLinked to original sources

bioRxiv2026

Reverse molecular pharmacology identifies the non-canonical axis of IRAK as a chemoresistance factor in neuroblastoma

Owing to chemoresistance, the prognosis of relapsed neuroblastoma is dismal with less than 10% of patients surviving after 5 years. We developed a reverse molecular pharmacology approach that is based on high-throughput drug screening coupled with chemo-informatic and transcriptomic analyses. This led to the identification of IRAK1 as a key chemoresistance factor in neuroblastoma. By performing functional and pharmacological drug combination screens targeting IRAK1, we revealed a synergy between IRAK1 inhibition/silencing and BET, EGFR and mTOR inhibitors as well as microtubule-targeting agents. The synergistic combination of microtubule-targeting agent, vincristine and IRAK inhibitors was then confirmed in tumor spheroids, patient-derived tumoroids and a syngeneic orthotopic mouse model. Mechanistically, IRAK inhibition potentiated the pro-apoptotic and cell cycle arrest properties of vincristine via a pathway involving the PIDDosome complex rather than its canonical MyDDosome axis. Altogether, this study represents a proof-of-concept of our reverse molecular pharmacology approach to quickly develop biology-guided drug combinations, that could be applied to any other human diseases.

cancer biology↗

bioRxiv2024

NCLX controls hepatic mitochondrial Ca2+ extrusion and couples hormone-mediated mitochondrial Ca2+ oscillations with gluconeogenesis

Hepatic Ca2+ signaling is emerging as a key factor in mediating gluconeogenesis. However, the identity of the hepatic mitochondrial Ca2+ transporter is controversial and the role of mitochondria in controlling hormonal Ca2+ signaling and linking them to metabolic activity is poorly understood. We first interrogated the role of the mitochondrial Na+/Ca2+ exchanger NCLX by triggering cytosolic Ca2+ purinergic signaling in primary hepatocytes, and Ca2+ responses in isolated mitochondria from WT, global NCLX KO, and conditional hepatic NCLX KO mice models. We monitored a higher rate of Na+-dependent mitochondrial Ca2+ efflux in NCLX-expressing hepatocytes, indicating that it constitutes the major Ca2+ efflux pathway. We then asked if NCLX is controlling the hormone-dependent mitochondrial Ca2+ oscillations by employing physiological concentrations of glucagon and vasopressin. Consistent with previous studies, hormone applications triggered mitochondrial Ca2+ oscillations in WT hepatocytes. In NCLX KO hepatocytes the cytosolic oscillations persisted, however, the mitochondrial Ca2+ oscillations were suppressed. To further understand the metabolic role of NCLX in the hepatic system, we examined gluconeogenic function in vivo and ex vitro by monitoring hepatic glucose production. We found that blood glucose dropped faster in the conditional KO mice and their hepatic glucagon-dependent glucose production was reduced, indicating that gluconeogenesis was impaired in hepatic conditional NCLX KO mice. Taken together, our results indicate that NCLX is the primary Ca2+ extruder in hepatocytes and is required for mediating the hormone-dependent mitochondrial Ca2+ oscillations and gluconeogenesis. SignificanceHepatic Ca2+ signaling is crucial for gluconeogenesis, but the mitochondrial control of this process is not resolved. This study identifies the mitochondrial transporter, NCLX, as a critical link between hormonal-dependent mitochondrial Ca2+ oscillations and gluconeogenesis. We first show that NCLX is the major hepatic mitochondrial efflux pathway. We then demonstrate that NCLX is required for glucagon-dependent mitochondrial Ca2+ oscillations and the acceleration of mitochondrial oxidative function. Using a conditional hepatic NCLX-null mouse model, we show that NCLX is required for maintaining hepatic glucose production during fasting and in response to glucagon stimulation. Overall, the study identifies NCLX as the integrator of hepatic mitochondrial Ca2+ signaling, required for gluconeogenesis.

physiology↗

bioRxiv2023

Combining Bacteriophage and Vancomycin is Efficacious Against MRSA biofilm-like Aggregates Formed in Synovial Fluid

BackgroundBiofilm formation is a major clinical challenge contributing to treatment failure of periprosthetic joint infection (PJI). Lytic bacteriophages (phages) can target biofilm associated bacteria at localized sites of infection. The aim of this study is to investigate whether combination therapy of phage and vancomycin is capable of clearing Staphylococcus aureus biofilm-like aggregates formed in human synovial fluid. MethodsIn this study, S. aureus BP043, a PJI clinical isolate was utilized. This strain is a methicillin-resistant S. aureus (MRSA) biofilm-former. Phage Remus, known to infect S. aureus, was selected for the treatment protocol. BP043 was grown as aggregates in human synovial fluid. The characterization of S. aureus aggregates was assessed for structure and size using scanning electron microscopy (SEM) and flow cytometry, respectively. Moreover, the formed aggregates were subsequently treated in vitro with: a) phage Remus ([~]108 plaque-forming units (PFU)/mL), b) vancomycin (500 {micro}g/mL), or c) phage Remus ([~]108 PFU/mL) followed by vancomycin (500 {micro}g/mL), for 48 hours. Bacterial survival was quantified by enumeration (colony-forming units (CFU)/ mL). The efficacy of phage and vancomycin against BP043 aggregates was assessed in vivo as individual treatments and in combination. The in vivo model utilized Galleria mellonella larvae which were infected with BP043 aggregates pre-formed in synovial fluid. ResultsSEM images and flow cytometry data demonstrated the ability of human synovial fluid to promote formation of S. aureus aggregates. Treatment with Remus resulted in significant reduction in viable S. aureus residing within the synovial fluid aggregates compared to the aggregates that did not receive Remus (p < 0.0001). Remus was more efficient in eliminating viable bacteria within the aggregates compared to vancomycin (p < 0.0001). Combination treatment of Remus followed by vancomycin was more efficacious in reducing bacterial load compared to using either Remus or vancomycin alone (p = 0.0023, p < 0.0001, respectively). When tested in vivo, this combination treatment also resulted in the highest survival rate (37%) 96 hours post-treatment, compared to untreated larvae (3%; p < 0.0001). ConclusionWe demonstrate that combining phage Remus and vancomycin led to synergistic interaction against MRSA biofilm-like aggregates in vitro and in vivo.

microbiology↗

bioRxiv2018

NCLX prevents cell death during adrenergic activation of the brown adipose tissue

A sharp increase in mitochondrial Ca2+ marks the activation of the brown adipose tissue (BAT) thermogenesis, yet the mechanisms preventing Ca2+ deleterious effects are poorly understood. Here, we show that adrenergic stimulation of BAT activates a PKA-dependent mitochondrial Ca2+ extrusion via the mitochondrial Na+/Ca2+ exchanger, NCLX. Adrenergic stimulation of NCLX-ablated brown adipocytes (BA) induces a profound mitochondrial Ca2+ overload and impaired uncoupled respiration. Core body temperature, PET imaging and VO2 measurements confirm a BAT specific thermogenic defect in NCLX-null mice.\n\nWe show that mitochondrial Ca2+ overload induced by adrenergic stimulation of NCLX-null BAT, triggers the opening of the mitochondrial permeability transition pore (mPTP), leading to remarkable mitochondrial swelling, Cytochrome c release and cell death in BAT. However, treatment with mPTP inhibitors rescue mitochondrial respiratory function and thermogenesis in NCLX-null BA, in vitro and in vivo.\n\nOur findings identify a novel pathway enabling non-lethal mitochondrial Ca2+ elevation during adrenergic stimulation of uncoupled respiration. Deletion of NCLX transforms the adrenergic pathway responsible for the stimulation of thermogenesis into a death pathway.

physiology↗

bioRxiv2017

Gene nucleotide composition accurately predicts expression and is linked to topological chromatin domains

Gene expression is orchestrated by distinct regulatory regions (e.g. promoters, enhancers, UTRs) to ensure a wide variety of cell types and functions. A challenge is to identify which regulatory regions are active, what are their associated features and how they work together in each cell type. Several approaches have tackled this problem by modeling gene expression based on epigenetic marks (e.g. ChIP-seq, methylation, DNase hypersensitivity), with the ultimate goal of identifying driving genomic regions and mutations that are clinically relevant in particular in precision medicine. However, these models rely on experimental data, which are limited to specific samples (even often to cell lines) and cannot be generated for all regulators and all patients. In addition, we show here that, although these approaches are accurate in predicting gene expression, their biological interpretation can be misleading. Finally these methods are not designed to capture potential regulation instructions present at the sequence level, before the binding of regulators or the opening of the chromatin. We develop here a method for predicting mRNA levels based solely on sequence features collected from distinct regulatory regions, which is as accurate as methods based on experimental data. Our approach confirms the importance of nucleotide composition in predicting gene expression and ranks regulatory regions according to their contribution. It also unveils strong influence of gene body sequence, in particular introns. We further provide evidence that the contribution of nucleotide content can be linked to co-regulations associated with genome 3D architecture and to associations of genes within topologically associated domains.

bioinformatics↗